Carboplatin and etoposide in previously treated colorectal cancer patients

G. Colucci, E. Maiello, F. Giuliani, R. A. Cifarelli, F. Giotta

Research output: Contribution to journalArticlepeer-review


Aims and background: Salvage treatment of advanced colorectal cancer patients has not been well defined as yet, and new potentially active drugs or combinations should be evaluated for these situations. Methods: From February 1993 to September 1993, the combination of carboplatin (CBDCA) and etoposide (VP-16), both as 100 mg/m2 for three consecutive days, was administered to 17 colorectal cancer patients who had been previously subjected to FA-FU combination chemotherapy. The CBDCA+VP-16 treatment was repeated every 3 weeks. A total of 58 cycles was administered, and 16 patients were evaluable for response. Results: There was no objective response, but 2 stable diseases and 14 progressive diseases were observed. Toxicity was mild, with no WHO 3-4 grade toxicity. Conclusion: this combination chemotherapy was judged ineffective for pretreated colorectal cancer patients.

Original languageEnglish
Pages (from-to)36-38
Number of pages3
Issue number1
Publication statusPublished - 1995


  • carboplatin + etoposide chemotherapy
  • colorectal cancer
  • salvage treatment

ASJC Scopus subject areas

  • Cancer Research


Dive into the research topics of 'Carboplatin and etoposide in previously treated colorectal cancer patients'. Together they form a unique fingerprint.

Cite this